2022 1 Tier Standard - SCHA

2022 Step Therapy Criteria

CURRENT AS OF 12/01/2022

anticonvulsant step therapy

Products Affected

- APTIOM TABLET 200 MG ORAL
- APTIOM TABLET 400 MG ORAL
- APTIOM TABLET 600 MG ORAL
- APTIOM TABLET 800 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 50 & 200 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of two of the following medications: carbamazepine, carbamazepine ER, divalproex sodium, divalproex sodium ER, gabapentin, lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, oxcarbazepine, valproic acid, zonisamide, phenytoin, phenytoin ER, felbamate, ethosuxamide, topiramate, primidone, Dilantin, phenobarbital, or tiagabine. Step 2: Once two of the medications listed in Step 1 have been tried, patients can receive therapy with Aptiom, Spritam, or Xcopri.

antidepressant step therapy

Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of two of the following medications: citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, venlafaxine ER or desvenlafaxine ER. Step 2: Once two of the medications listed in step 1 have been tried, patient can receive therapy with Fetzima.

brinzolamide step therapy

Products Affected

- *brinzolamide suspension 1 % ophthalmic*

Details

Criteria	Step 1: First line therapy should be a documented trial of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, the patient can receive therapy with brinzolamide.

combivent step therapy

Products Affected

- COMBIVENT RESPIMAT AEROSOL SOLUTION 20-100 MCG/ACT INHALATION

Details

Criteria	Step 1: First line therapy should be a documented trial of Anoro Ellipta, Bevespi Aerosphere, or Stiolto Respimat. Step 2: Once Anoro Ellipta, Bevespi Aerosphere, or Stiolto Respimat has been tried, patients can receive therapy with Combivent Respimat.

drizalma step therapy

Products Affected

- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 20 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 30 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 40 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 60 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of generic duloxetine.Step 2: Once generic duloxetine has been tried, patients can receive therapy with Drizalma.

febuxostat step therapy

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial of allopurinol tablet. Step 2: Once allopurinol tablet has been tried, patients can receive therapy with Febuxostat.

ongentys step therapy

Products Affected

- ONGENTYS CAPSULE 25 MG ORAL
- ONGENTYS CAPSULE 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, patients can receive therapy with Ongentys.

rhopressa step therapy

Products Affected

- RHOPRESSA SOLUTION 0.02 %
  OPHTHALMIC

Details

Criteria	Step 1: First line therapy should be a documented trial of latanoprost or travoprost. Step 2: Once latanoprost or travoprost has been tried, patients can receive therapy with Rhopressa.

rivastigmine patch step therapy

Products Affected

- *rivastigmine patch 24 hour 13.3 mg/24hr transdermal*
- *rivastigmine patch 24 hour 4.6 mg/24hr transdermal*
- *rivastigmine patch 24 hour 9.5 mg/24hr transdermal*

Details

Criteria	Step 1: First line therapy should be a documented trial of rivastigmine capsule. Step 2: Once rivastigmine capsule has been tried, patients can receive therapy with rivastigmine patches.

topical immunomodulators step therapy

Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

Details

Criteria	Step 1: First line therapy should be a documented trial of two topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, patients can receive therapy with generic pimecrolimus or generic topical tacrolimus.

urinary incontinence agents step therapy

Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- *fesoterodine fumarate er tablet extended release 24 hour 4 mg oral*
- *fesoterodine fumarate er tablet extended release 24 hour 8 mg oral*
- *tolterodine tartrate er capsule extended release 24 hour 2 mg oral*
- *tolterodine tartrate er capsule extended release 24 hour 4 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial of oxybutynin, oxybutynin ER, trospium, tolterodine, or solifenacin. Step 2: Second line therapy should be tolterodine ER, trospium ER, darifenacin ER, or fesoterodine ER.

zafirlukast step therapy

Products Affected

- *zafirlukast tablet 10 mg oral*
- *zafirlukast tablet 20 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial of montelukast. Step 2: Once montelukast has been tried, patients may receive therapy with zafirlukast.

Index

A
APTIOM TABLET 200 MG ORAL..... 1
APTIOM TABLET 400 MG ORAL..... 1
APTIOM TABLET 600 MG ORAL..... 1
APTIOM TABLET 800 MG ORAL..... 1
B
brinzolamide suspension 1 % ophthalmic... 3
C
COMBIVENT RESPIMAT AEROSOL SOLUTION 20-100 MCG/ACT INHALATION..... 4
D
darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral..... 11
darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral..... 11
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 20 MG ORAL 5
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 30 MG ORAL 5
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 40 MG ORAL 5
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 60 MG ORAL 5
F
febuxostat tablet 40 mg oral..... 6
febuxostat tablet 80 mg oral..... 6
fesoterodine fumarate er tablet extended release 24 hour 4 mg oral..... 11
fesoterodine fumarate er tablet extended release 24 hour 8 mg oral..... 11
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL ... 2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL 2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL 2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL 2
FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL..... 2
O
ONGENTYS CAPSULE 25 MG ORAL.... 7
ONGENTYS CAPSULE 50 MG ORAL.... 7
P
pimecrolimus cream 1 % external..... 10
R
RHOPRESSA SOLUTION 0.02 % OPHTHALMIC 8
rivastigmine patch 24 hour 13.3 mg/24hr transdermal..... 9
rivastigmine patch 24 hour 4.6 mg/24hr transdermal..... 9
rivastigmine patch 24 hour 9.5 mg/24hr transdermal..... 9
S
SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL 1
SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL 1
SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL 1
SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL 1
T
tacrolimus ointment 0.03 % external 10
tacrolimus ointment 0.1 % external 10
tolterodine tartrate er capsule extended release 24 hour 2 mg oral..... 11
tolterodine tartrate er capsule extended release 24 hour 4 mg oral..... 11
trospium chloride er capsule extended release 24 hour 60 mg oral..... 11
X
XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL 1
XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 50 & 200 MG ORAL 1
XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL 1

XCOPRI TABLET 100 MG ORAL 1
XCOPRI TABLET 150 MG ORAL 1
XCOPRI TABLET 200 MG ORAL 1
XCOPRI TABLET 50 MG ORAL 1
XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL..... 1
XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL..... 1
XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL..... 1

Z

zafirlukast tablet 10 mg oral 12
zafirlukast tablet 20 mg oral 12